British Journal of Dermatology · 2008 · 66 citations · 40 references
MedicineHematologyImmunologyClinical ImmunologyHematopathologyImmunopathologyClinical HematologyDiagnostic ImmunologyPeripheral Blood MorphologyPeripheral Blood Smear InterpretationTumor AntigensTumor-associated AntigensDiagnostic AntigensFlow Cytometry ImmunophenotypingMultiparameter Flow CytometryPeripheral Blood Immune BiomarkersPeripheral Blood Lymphocyte AnalysisPeripheral Blood Smear MorphologySézary SyndromeT-cell Biomarkers
BACKGROUND: Diagnosis of Sézary syndrome (SS)-defining blood involvement is hampered by the lack of Sézary cell-specific markers and nonspecific morphology of the tumour cells. OBJECTIVES: To identify the most reliable and easy to use markers for the diagnosis of SS-defining blood involvement. METHODS: We studied 17 patients with SS and 11 control patients. We used flow cytometry for the detection of T-cell antigens (CD3, CD4, CD7 and CD8), expression of the Sézary cell-associated marker CD158k and T-cell receptor (TCR)-Vbeta chain. Additionally, Sézary cells were identified by peripheral blood smear for lymphocytes with cerebriform nuclei. RESULTS: It was not possible to diagnose blood involvement in all patients with SS by a single marker or method, although none of the markers was increased in the control population. Sézary cells were detected by blood smears in 13 of 17 (76%), by flow cytometry by their CD4+ CD7- CD3(dim) phenotype (> 1000 cells microL(-1)) in 13 of 17 (76%) and by expression of CD158k in 11 of 17 (65%) patients with SS. A specific T-cell clone was identified by identical TCR-Vbeta chain expression in 12 of 17 (71%) patients with SS. The identification of Sézary cells in individual patients varied for the different markers investigated. CONCLUSIONS: The combination of identifying CD4+ CD7- CD3(dim) cells, TCR-Vbeta chain and CD158k expression allowed a definite identification of SS-defining blood involvement in every individual patient. All of these markers can be measured by flow cytometry which would avoid time-consuming analysis of blood smears. These markers would also be suitable to monitor tumour cell load during therapy.
40
Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas.
Bunn Pa, Lamberg Si · PubMed · 1979 · 544 citations
Medicine, Dermatology, Oncology +11
Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells
Carole L. Berger, Robert E. Tigelaar, Justine V. Cohen et al. · Blood · 2004 · 245 citations
Medicine, Dermatology, Oncology +11